JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


Anesth Analg 1989; 68:51-56
© 1989 International Anesthesia Research Society
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lehmanna, K. A.
Right arrow Articles by Arabatsis, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lehmanna, K. A.
Right arrow Articles by Arabatsis, P.

Failure of Proglumide, a Cholecystokinin Antagonist, to Potentiate Clinical Morphine Analgesia

A Randomized Double-Blind Postoperative Study Using Patient-Controlled Analgesia (PCA)

Klaus A. Lehmanna, MD, PhD, Michaela Schlüsener, and Panagiotis Arabatsis

Received from the Department of Anesthesiology, University of Cologne, Federal Republic of Germany.

Abstract

The potential clinical utility of drug interactions between morphine and the cholecystokinin antagonist proglumide was examined in 80 postoperative patients suffering from moderate to severe pain. Four groups of ASA I-III patients (mean age 51 years, mean weight 72 kg) recovering from major abdominal or gynecological surgery (mean duration of surgery 141 minutes) performed under balanced anesthesia (midazolam, droperidol, fentanyl, N2O, enflurane) were randomly assigned to self-administer morphine-proglumide mixtures on the first postoperative day (ODAC; morphine demand dose 3 mg; infusion rate 0.36 mg/hr; lockout time 2 minutes; hourly maximum dose 15 mg/hr; proglumide doses per demand 0, 50 µg, 100 µg, or 50 mg). Morphine consumption, actual as well as retrospective pain scores (0–5) and side effects were evaluated. Mean duration of patient-controlled analgesia (PCA) in the subgroups was 17–19 hours, during which time 24.6 ± 9.5 to 28.0 ± 3.4 µg morphine·kg–1·hr–1 was given. There were no statistically significant differences between the groups either for drug consumption, pain scores, or side effects. It is therefore concluded that proglumide does not potentiate morphine analgesia in a clinical (postoperative) setting.

Key Words: ANALGESICS—morphine • DRUG INTERACTIONS—cholecystokinin, proglumide • PAIN, POSTOPERATIVE—patient-controlled analgesia







Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 1989 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 1989 by the International Anesthesia Research Society.